Get the Stockscreener App
10.82
0.00%
0.00
After Hours:
10.95
0.13
+1.20%
Niagen Bioscience Inc stock is traded at $10.82, with a volume of 871.13K.
It is up +0.00% in the last 24 hours and up +39.07% over the past month.
Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.
See More
Previous Close:
$10.82
Open:
$10.87
24h Volume:
871.13K
Relative Volume:
1.42
Market Cap:
$852.29M
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+9.51%
1M Performance:
+39.07%
6M Performance:
+0.00%
1Y Performance:
+0.00%
1-Day Range:
$10.60
$10.96
1-Week Range:
$10.12
$11.16
52-Week Range:
$5.33
$11.16
Niagen Bioscience Inc Stock (NAGE) Company Profile
Name
Niagen Bioscience Inc
Sector
Industry
Phone
310-388-6706
Address
10900 WILSHIRE BLVD, LOS ANGELES
Compare NAGE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
10.82 | 778.24M | 0 | 0 | 0 | 0.00 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-27-25 | Initiated | Canaccord Genuity | Buy |
| Aug-16-22 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-11-22 | Downgrade | B. Riley Securities | Buy → Neutral |
| Mar-08-22 | Initiated | ROTH Capital | Buy |
| Oct-16-19 | Initiated | Oppenheimer | Outperform |
| Feb-14-19 | Initiated | B. Riley FBR | Buy |
| Nov-27-17 | Resumed | H.C. Wainwright | Buy |
| Sep-25-17 | Initiated | Ladenburg Thalmann | Buy |
| Jan-03-17 | Initiated | Rodman & Renshaw | Buy |
View All
Niagen Bioscience Inc Stock (NAGE) Latest News
Niagen Bioscience (NASDAQ:NAGE) Now Covered by Canaccord Genuity Group - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Sets New 52-Week HighHere's What Happened - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Coverage Initiated by Analysts at Canaccord Genuity Group - Defense World
Canaccord Genuity Initiates Coverage of Niagen Bioscience (NAGE) with Buy Recommendation - Nasdaq
Canaccord Genuity Initiates Niagen Bioscience at Buy With $13 Price Target - marketscreener.com
Canaccord starts Niagen Bioscience at Buy on ‘unique opportunity’ - TipRanks
Niagen Bioscience (NAGE) Receives Positive Outlook with $13 Pric - GuruFocus
Niagen Bioscience (NAGE) Receives Positive Outlook with $13 Price Target | NAGE Stock News - GuruFocus
Canaccord Analyst Recommends Buying Niagen Bioscience (NAGE) Stock | NAGE Stock News - GuruFocus
Niagen Bioscience: Overbought After Rally (NASDAQ:NAGE) - Seeking Alpha
3 Stocks That May Be Trading Below Their Estimated Value - simplywall.st
Niagen Bioscience (NASDAQ:NAGE) Reaches New 12-Month HighHere's Why - MarketBeat
Niagen Bioscience Inc (NASDAQ:NAGE) Q1 2025 Earnings Call Transcript - MSN
Earnings Beat: Niagen Bioscience, Inc. Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models - simplywall.st
Niagen Bioscience Reaches Analyst Target Price - Nasdaq
Ratios Uncovered: Breaking Down Niagen Bioscience Inc (NAGE)’s Trailing Twelve Months Metrics - DWinneX
Niagen Bioscience: Q1 Earnings Snapshot - New Haven Register
Niagen Bioscience Inc (NAGE) Q1 2025 Earnings Call Highlights: Strong Revenue Growth and ... - Yahoo Finance
Niagen Bioscience, Inc. Reports First Quarter 2025 Financial Results and Increases Outlook - BioSpace
Niagen Bioscience Reports Strong Q1 2025 Growth - TipRanks
Earnings call transcript: Niagen Bioscience Q1 2025 sales surge, stock rises - Investing.com Nigeria
Niagen Bioscience Inc (NAGE) Q1 2025 Earnings: EPS of $0.07 Beats Estimate, Revenue Surges to $30.5 Million - GuruFocus
Niagen Bioscience (NAGE) Reports Record Q1 Revenue with Strong G - GuruFocus
Niagen Bioscience (NAGE) Q1 Earnings and Revenues Beat Estimates - Yahoo Finance
Niagen Bioscience Q1 2025 slides: revenue jumps 38%, raises full-year outlook - Investing.com
Niagen Bioscience, Inc. SEC 10-Q Report - TradingView
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 | NAGE Stock News - GuruFocus
What's Next: Niagen Bioscience's Earnings Preview - Nasdaq
Niagen Bioscience Inc expected to post earnings of 2 cents a shareEarnings Preview - TradingView
Niagen Bioscience (NAGE) Expands Clinical Network with New Clinics - GuruFocus
Niagen IV therapy expands to nearly 600 clinics nationwide By Investing.com - Investing.com India
Niagen IV therapy expands to nearly 600 clinics nationwide - Investing.com
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide | NAGE Stock News - GuruFocus
Niagen Bioscience Announces Pharmaceutical-Grade Niagen® IV Is Now Available in Almost 600 Clinics Nationwide - Nasdaq
Niagen Bioscience adds aging expert to advisory board By Investing.com - Investing.com India
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board | NAGE Stock News - GuruFocus
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advis - GuruFocus
Niagen Bioscience Welcomes Dr. Pinchas Cohen to Scientific Advisory Board - The Joplin Globe
Niagen Bioscience to Report First Quarter 2025 Financial Results on Wednesday, May 7, 2025 - Bluefield Daily Telegraph
Is Niagen Bioscience, Inc.'s (NASDAQ:NAGE) Latest Stock Performance A Reflection Of Its Financial Health? - simplywall.st
Niagen Bioscience Inc [NAGE] stock for 2,146 USD was acquired by Lopez Carlos Luis - knoxdaily.com
Is it possible to buy Niagen Bioscience Inc(NAGE) shares at a good price now? - uspostnews.com
Niagen Bioscience, Inc.'s (NASDAQ:NAGE) market cap up US$51m last week, benefiting both individual investors who own 36% as well as insiders - Yahoo Finance
Supplement Maker Rebrands - Los Angeles Business Journal
Niagen Bioscience Inc Stock (NAGE) Financials Data
There is no financial data for Niagen Bioscience Inc (NAGE). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
Niagen Bioscience Inc Stock (NAGE) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Lopez Carlos Luis | SVP, General Counsel |
Mar 07 '25 |
Buy |
7.86 |
273 |
2,146 |
2,251 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Option Exercise |
3.66 |
50,001 |
183,004 |
281,340 |
| Jaksch Frank L Jr | Director |
Dec 13 '24 |
Sale |
6.19 |
37,161 |
229,956 |
244,179 |
1.89%
3.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):